(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Capital Increase and Share Expansion of Controlled Subsidiary for Introduction of Investors

Summary by 6ix AI

Zhejiang Huahai Pharmaceutical Co., Ltd. announced a capital increase and share expansion for its controlled subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., to introduce external investors. The company plans to raise funds through external investors, including the Yangtze River Delta Venture Capital Guidance Fund, with a total investment not exceeding a specified amount. After the capital increase, Zhejiang Huahai will maintain a significant ownership stake in Huatai, ensuring it remains a consolidated subsidiary. The transaction has been approved by the company's board and does not constitute a related party transaction or a major asset restructuring. The announcement includes risk warnings regarding the completion of the investment agreements and the potential uncertainties involved in the transaction.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries